<DOC>
	<DOC>NCT02135029</DOC>
	<brief_summary>This study is a multicenter, double blinded, active and placebo controlled randomized clinical trial to demonstrate a superior lipid lowering effect of Bococizumab (PF-04950615; RN316) compared to placebo in subjects who are statin intolerant.</brief_summary>
	<brief_title>Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Hyperlipidemia Statin Intolerant Fasting LDLC &gt; = 70 mg/dL Fasting TG &lt; = 400 mg/dL Pregnant or breastfeeding females Cardiovascular or cerebrovascular event or procedure within 90 days Severe or lifethreatening adverse events with past use of statins Poorly controlled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hyperlipidemia</keyword>
	<keyword>statin intolerance</keyword>
</DOC>